Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab tr...

Full description

Bibliographic Details
Main Authors: Duarte Diana Borges, Silva Ana Martins da, Freitas Claudia, Cardoso Helena
Format: Article
Language:English
Published: Sciendo 2021-07-01
Series:Endocrine Regulations
Subjects:
ocrelizumab
graves´ disease
immune reconstitution therapy
multiple sclerosis
Online Access:https://doi.org/10.2478/enr-2021-0018

Similar Items

Similar Items